<DOC>
	<DOC>NCT00210938</DOC>
	<brief_summary>The purpose of this study is to compare the clinical response rates of doripenem versus a comparator antibiotic in treatment of hospitalized patients with complicated intra-abdominal infections.</brief_summary>
	<brief_title>Doripenem in the Treatment of Complicated Intra-Abdominal Infections</brief_title>
	<detailed_description>Doripenem is an antibiotic medication not yet approved by the US FDA. This is a phase 3, multicenter, prospective, randomized, double-blind study of intravenous doripenem versus a comparator antibiotic to assess the effectiveness and safety of doripenem in the treatment of complicated intra-abdominal infections in hospitalized adults. The primary endpoint is the clinical response rate measured at late follow-up visit. The patients will receive either doripenem or comparator; treatment duration is 5 to 14 days.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Appendicitis</mesh_term>
	<mesh_term>Peritonitis</mesh_term>
	<mesh_term>Cholecystitis</mesh_term>
	<mesh_term>Acalculous Cholecystitis</mesh_term>
	<mesh_term>Intraabdominal Infections</mesh_term>
	<criteria>Has a requirement for surgical intervention within 24 hours of study entry Requirement of antibacterial therapy in addition to surgical intervention in certain intraabdominal infections. Female patients who are pregnant, nursing, or if of child bearing potential not using a medically accepted, effective method of birth control Any rapidlyprogressing disease or immediately lifethreatening illness.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Complicated Intra-Abdominal Infections</keyword>
	<keyword>Appendicitis</keyword>
	<keyword>Cholecystitis</keyword>
	<keyword>Peritonitis</keyword>
</DOC>